Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07425587 · ClinicalTrials.gov registry record

Multicenter Symphony™ IL-6 Monitoring Sepsis ED Pilot Study

A clinical trial, sponsored by Bluejay Diagnostics.

Recruiting
Registry status
450
Enrollment target

NCT07425587: Recruiting study, sponsored by Bluejay Diagnostics.

NCT07425587 is a clinical trial that is actively recruiting participants, run by Bluejay Diagnostics. The registered enrollment target is 450 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07425587 is actively recruiting participants, sponsored by Bluejay Diagnostics.

RECRUITING
Registry status
450 participants
Enrollment target

Study Summary

The primary objective of this study is to establish an IL-6 concentration cutoff that predicts sepsis or septic shock (according to the Third International Consensus Definitions (Sepsis-3 criteria)) in patients who are admitted or are intended to be admitted to the hospital from the emergency department with suspected infection.

Trial Details

FieldValue
Enrollment Target 450 participants
Start Date 2026-05-04
Est. Completion 2026-12-30
Bluejay Diagnostics

3 total trials

What NCT07425587 shows while recruiting

NCT07425587 is an observational study that tracks outcomes without assigning an intervention. The registered 450 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT07425587 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07425587 about?

NCT07425587 is a clinical study titled "Multicenter Symphony™ IL-6 Monitoring Sepsis ED Pilot Study". The primary objective of this study is to establish an IL-6 concentration cutoff that predicts sepsis or septic shock (according to the Third International Consensus Definitions (Sepsis-3 criteria)) in patients who are admitted or are intended to be admitted to the hospital from the emergency depart...

What is the current status of trial NCT07425587?

This trial is currently recruiting. The enrollment target is 450 participants. The study started on 2026-05-04. Estimated completion is 2026-12-30.

Who is sponsoring clinical trial NCT07425587?

This trial is sponsored by Bluejay Diagnostics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00515060 · 450 participants

    Psychophysical Studies of Cancer Therapy Pain

  • NCT01257269 · 450 participants

    Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)

  • NCT03047161 · 450 participants

    Electrophysiology of Fetal Arrhythmia

  • NCT03269630 · 450 participants

    New Orleans Pulmonary Hypertension Biobank

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07425587, the US trial registry maintained by the National Library of Medicine. NCT07425587 (mid enrollment · none site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.